New combo aims to erase hidden myeloma after transplant
NCT ID NCT05690984
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests a three-drug combination (isatuximab, lenalidomide, and dexamethasone) in 30 adults with multiple myeloma who still have tiny amounts of cancer cells in their bone marrow after a stem cell transplant. The goal is to see if the treatment can make those leftover cells undetectable. Participants will take the drugs for several months, and the study will check if the cancer stays away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.